Quick Answer
Xeris Biopharma Holdings, Inc. reported Total Assets of $383.53 million for fiscal year 2025.
Xeris Biopharma Holdings, Inc. Total Assets — Annual History
| Fiscal Year | Total Assets | YoY Change |
|---|---|---|
| 2025 | $383.53M | +18.7% |
| 2024 | $323.06M | +0.1% |
| 2023 | $322.60M | -6.4% |
| 2022 | $344.52M | +13.2% |
| 2021 | $304.36M | +91.2% |
| 2020 | $159.15M | — |
Quarterly Total Assets
| Quarter Ending | Total Assets | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $370.19M | +15.3% | +10.6% |
| June 30, 2025 | $334.69M | +0.9% | +6.1% |
| March 31, 2025 | $315.45M | -6.3% | -2.4% |
| December 31, 2024 | $323.06M | +0.1% | +0.6% |
| September 30, 2024 | $321.10M | -2.0% | -3.2% |
| June 30, 2024 | $331.73M | +0.9% | -1.5% |
| March 31, 2024 | $336.62M | +4.7% | +4.3% |
| December 31, 2023 | $322.60M | -6.4% | -1.6% |
- Xeris Biopharma Holdings, Inc. showed an increase of +18.7% in Total Assets compared to the prior fiscal year.
- Over the 2020–2025 period, Xeris Biopharma Holdings, Inc.’s total assets has grown by 141.0% (from $159.15 million to $383.53 million).
- The most recent figure is from Xeris Biopharma Holdings, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 2, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: